Moderate to vigorous physical activity (minutes/d) [ · adults
1 finding from 1 review
Moderate gingival inflammation / gingival health · Persons with disabilities (children and adults with autism, Down syndrome, cerebral palsy, hearing impairment, or multiple disabilities)…
Gingival inflammation is common among persons with disabilities in Saudi Arabia (moderate-to-severe up to about 60%), reported narratively without a pooled comparative estimate (ungraded).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower moderate‐to‐severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Major neurological disability at 2 years of age (Defined as any of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (developmental quoti... · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in major neurological disability at 2 years of age (Defined as any of… compared with placebo (low certainty).
1 finding from 1 review
Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Moderate or severe OHSS · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol · assisted reproduction technology cycles
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Moderate or severe OHSS ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS · assisted reproduction technology cycles
It is very uncertain whether summary of findings table ‐ Progestagen changes moderate or severe OHSS compared with gnRH agonist (very low certainty).
1 finding from 1 review
Moderate or severe OHSS · assisted reproduction technology cycles
1 finding from 1 review
5a. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5a.Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5c. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (26 studies, 4949 participants in the analysis) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (38 studies, 6525 participants in analyses) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (36 studies, 6263 participants) in the analysis Interventions: optical and pharmacological Comparator:…
1 finding from 1 review
Intervention not reported
Moderate‐dose atropine (0.1% to < 0.5%) · children with progressive myopia (21 studies, 4169 participants in the analysis) Interventions: optical and pharmacological Comparator:…
1 finding from 1 review